Adopt AI in your research program without losing control of patient data, model lineage, or regulatory standing.
Schedule a Sovereign AI ConversationI've built a privacy-first email automation system that demonstrates sovereign AI patterns at the application layer — local-by-default LLM, HIPAA-mode enforcement in code, audit-chain logging compatible with §164.312(b). It's both a product useful to research programs and a reference implementation of how sovereign AI ships.
Sovereign AI is the deliberate practice of deploying artificial intelligence so that your research program retains control over three things: patient and study data, the models themselves (including weights, fine-tuning, and lifecycle), and the audit trail of every decision. Sovereign AI keeps these inside your institutional regulatory perimeter rather than handing them to a third-party SaaS provider.
For medical research, sovereign AI is not optional. It is the only AI adoption pattern that aligns with how IRBs, HIPAA, FDA, NIH, and your own institutional data governance actually work. Every other path forces a choice between AI capability and regulatory standing — and that choice can end a research program.
Sovereign AI is also the discipline that makes AI-assisted research publishable. Reproducibility, model lineage, and audit trails are increasingly required by journals, funders, and regulators. Closed-weight commercial models with vendor-controlled versioning fail those tests.
Regulators, funders, IRBs, and journals are not waiting for research programs to figure AI out. The rules are being written now, and consumer or SaaS AI usage in research is already a compliance problem under one or more of these:
Implication: A research program using ChatGPT on de-identified data may already be in violation of its IRB protocol, its grant terms, its data use agreements with collaborating institutions, and the publication standards of its target journals — simultaneously. Discovering this during an audit, after a publication, or after a data breach is the worst time to find out.
Most existing informed consent forms do not cover third-party AI processing of patient data. Using consumer or SaaS AI on study data can place your program out of compliance with its own approved protocol — an IRB violation regardless of whether the data was de-identified.
Re-identification attacks on "de-identified" data fed to commercial AI are well-documented. PHI leakage through prompts is a notifiable incident under HIPAA. Once data is in a third-party model, it cannot be retracted — the disclosure has already happened.
Closed-weight models with versions you do not control mean your published results cannot be reproduced. Journals are starting to reject AI-assisted analyses without provenance and audit trails. Vendor model deprecations destroy reproducibility for any work depending on them.
NIH, NSF, DARPA, DOE data governance terms are increasingly incompatible with consumer AI. Institutional review of research AI usage is intensifying. A grant violation can mean funding clawback, future award ineligibility, and institutional reputation damage.
Sovereign AI for research is not a single product. It is a layered architecture that integrates with your institutional identity, security, IRB administration, and grants management systems. Federated learning gets first-class treatment because multi-site research collaboration is the norm.
Institutional HPC, sovereign-cloud research enclaves (AWS GovCloud, Azure for Research, GCP Sovereign Controls), or on-prem GPU clusters. Compatible with existing IRB-approved data handling environments.
Open-weight foundation models (Llama 3, Mistral) plus biomedical-specific open models (BioMedLM, Llama-Med variants, ClinicalBERT). Fine-tuning infrastructure for domain-specific performance.
Federated training and inference for multi-site cohorts and rare disease consortia. Share model improvements across collaborating institutions without sharing raw data — preserves DUAs, IRB boundaries, and patient consent scope.
vLLM, TGI, Triton for inference. LangChain, LlamaIndex, custom orchestration. Retrieval-augmented generation (RAG) over your sovereign research data sources, including REDCap, LIMS, EHR, imaging archives.
IRB-aware audit trails, FDA Part 11 compliance, model registry with version lineage tied to published results. Bias, drift, and equity monitoring. Reproducibility infrastructure that survives vendor changes.
Institutional SSO, study-team RBAC, data-use-agreement enforcement. Access boundaries match the IRB protocol — not a parallel access regime.
Prompt and response logs, model version tracking, performance monitoring, drift detection, audit log pipeline. Feeds your institutional compliance reporting and grant-required data governance documentation.
Most research programs are at stage 1 or 2 today. The transition from stage 2 to stage 3 is the highest-risk window: institutional AI policies exist, but architecture does not enforce them, and PIs are using consumer AI to keep grants on schedule.
Shadow AI everywhere. PIs and research staff using consumer AI on study data without inventory, policy, or oversight. Sensitive data is leaking through chatbots and unsanctioned enterprise tools.
Institutional AI usage policy. Approved tools list. Basic training. PIs know the rules but circumvent them when grant deadlines compete with compliance friction. Policy without architecture is hope.
DLP integrated. Sanctioned AI tools deployed with prompt logging. Unsanctioned tools blocked or monitored. Research AI inventory exists. Risk is reduced but not eliminated.
On-premises or sovereign-cloud AI deployed for research workloads. Open-weight models with biomedical fine-tuning. IRB-aware governance framework operational. Audit trails integrated with institutional compliance program.
Federated learning across institutional consortia for rare disease cohorts and multi-site studies. Mature MLOps with continuous evaluation. Audit trail integrated with grants compliance reporting. AI becomes a defensible institutional research capability.
2–4 weeks. Current-state inventory of AI usage in your program. IRB exposure, grant compliance review. Build-vs-buy-vs-host recommendation. Briefing for IRB, grants office, and institutional leadership.
4–8 weeks. Detailed architecture tailored to your program's IRB protocols, data use agreements, institutional infrastructure, and compliance program. Vendor-neutral.
8–16 weeks. Stand up working sovereign AI capability for one priority study or workload. Includes governance program, biomedical fine-tuning, and IRB-aware audit trail integration.
Fractional CTO retainer. Continuous strategy, architecture, and operational leadership as your sovereign AI program matures across studies, consortia, and grant cycles.
Often no, even for de-identified data. Re-identification risk, third-party AI processing not covered in informed consent, and data use agreement restrictions can all require IRB notification or amendment. The safe default is to confirm with your IRB before any AI processing of study data — including de-identified data — touches a third-party service.
Sovereign AI is generally easier to fit into existing DUAs than commercial AI. Federated learning architectures specifically allow you to honor "data does not leave institution X" clauses while still collaborating on AI model development. Many DUAs that prohibit commercial AI processing explicitly permit sovereign AI patterns.
If you used a closed-weight commercial model: your published findings are no longer reproducible by definition. Journals increasingly view this as a fatal flaw. Sovereign AI with version-locked open-weight models lets you preserve the exact model used for any published analysis — reproducibility for the lifetime of the work.
For most enterprise research workloads, yes. Open-weight models are competitive with closed-frontier models on classification, extraction, summarization, structured generation, and RAG-based question answering. Biomedical-tuned variants and domain fine-tuning on your data often outperform generic frontier models for specialized tasks. For frontier reasoning tasks, hybrid patterns (sovereign for sensitive workloads, commercial for low-sensitivity) are reasonable.
Rare disease cohorts are by definition small at any single site. Federated learning lets multiple institutions contribute to model training without sharing patient data — honoring HIPAA, IRB, DUA, and consent boundaries while still capturing the statistical power of a multi-site cohort. It is the natural pattern for rare disease consortia.
Highly variable. A sovereign-cloud research enclave for a focused workload can start in the low six figures all-in (compute, integration, governance). Institutional shared infrastructure spreads the cost across labs. Federated participation in an existing consortium can be much lower. Total cost is often comparable to or lower than per-seat enterprise AI subscriptions at scale, with the added benefit of being grant-allowable as data infrastructure.
If your IRB is asking "where will the data go?" and your PI is asking "when can we start using AI?" — those questions need the same answer. A 30-minute call helps identify your top exposure points, current maturity stage, and the highest-leverage next step.
Schedule a Sovereign AI Conversation